Tata Memorial Hospital, Mumbai, India
Mumbai, Maharashtra, 400012, India
Location status: Recruiting
Location contact
Ameya Puranik, DNB
PRINCIPAL_INVESTIGATOR
Farkhanda Khan, MSc
CONTACT
Sushil Yadav
CONTACT
912224177000 ext. 7019
NCT Number: NCT07342231
Pancreatic adenocarcinoma commonly referred to as pancreatic cancer is a cancer which is known to involve the pancreas and the surrounding structures like blood vessels, which makes it an aggressive cancer. Treatment of the cancer is decided by how much the disease has spread. It has been understood from recent studies that there are some components of the tumor which are not detected by standard CT scan. The tissue in the tumor microenvironment leads to further spread of tumor. The tissue which is seen near the tumor has many attachments on the surface which are currently being studied. One of the most common attachments is Fibroblast activation protein (FAP), which is seen on the surface of tumor tissue. A radioactive tracer Gallium-68 is attached to a small protein known as 'peptide' named 'FAP inhibitor (FAPi)' which shall bind to FAP. Then a PET scan will be performed which shall help in understanding how much of the tissue is seen on the scan in addition to the pancreatic tumor. The investigators shall assess whether the radiotracer (Gallium-68 labeled FAPi) binds to other sites like liver or other organs where the cancer is likely to spread. From the study, the investigators shall study whether the new scanning technique is beneficial as compared to the standard CT scanning. Hence, the investigators would perform Gallium-68-labeled FAPi PET scan in addition to the standard CT scan and compare the results.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Mumbai, Maharashtra, 400012, India
Location status: Recruiting
Ameya Puranik, DNB
PRINCIPAL_INVESTIGATOR
Farkhanda Khan, MSc
CONTACT
Sushil Yadav
CONTACT
912224177000 ext. 7019
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ga-68 FAPi PET/CT is a whole body scan to assess the FAP receptor expression in patients with pancreatic ductal adenocarcinoma
Other names: FAPi PET
Time frame: 6 and 12 months
To calculate sensitivity, specificity, positive predictive value and negative predictive value of quantitative and semi-quantitative parameters on FAPi PET
Contact information is provided by the study sponsor or research team.
Tata Memorial Hospital
Other Gov
FAP-1 Study: FAPi PET in Pancreatic Ductal Adenocarcinoma: A Prospective, Exploratory Study
Acronym: FAP-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07636382
Advanced Cancer, Celiac Disease
Toronto, Ontario, Canada
View Trial DetailsNCT07737171
Digestive System Diseases, Digestive System Neoplasms
Houston, Texas, United States
View Trial DetailsNCT06411691
Colonic Diseases, Colonic Neoplasms
Baltimore, Maryland, United States
View Trial DetailsNCT05227326
Adnexal Diseases, Bronchial Neoplasms
Scottsdale, Arizona, United States
View Trial Details